Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01763164
Title Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis|Novartis Pharmaceuticals
Indications

melanoma

Therapies

Dacarbazine

Binimetinib

Age Groups: adult
Covered Countries USA | CAN

Additional content available in CKB BOOST